From: Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study
Patients (%) on treatment
Vinorelbine dose arm (mg)
At 4 months
At 6 months
p value
30
25.9% (11.1-46.2%)
0.56
22.2% (8.6-57.7%)
0.39
40
33.3% (15.6-55.6%)
8.3% (1.0-27.0%)
50
18.2% (5.2-20.3%)
13.6% (2.9-34.9%)